Introduction: Laryngoscopy and intubation are noxious stimuli and are associated with haemodynamic responses in the form of laryngo-sympathetic stimulation which is manifested as hypertension, tachycardia. The magnitude of haemodynamic changes observed may be dependent on various factors such as the depth of anaesthesia, whether any measures are taken prior to airway manipulation, the anaesthetic agent used, the duration of laryngoscopy and intubation.

Aims: The present study is aimed to comparing the effectiveness
of two different doses of intravenous Dexmedetomidine, 0.6 μg/kg body weight and 1μg/kg body weight for attenuating haemodynamic response to laryngoscopy and endotracheal intubation and also to find out
any adverse effects.

Materials and methods : A Randomized, controlled study between 2 doses of intravenous dexmedetomidine–0.6 μg/kg body weight and 1 μg/kg body weight for attenuation of haemodynamic response to laryngoscopy and endotracheal intubation. was undertaken in 60 patients of either sex between 18 to and 55 yrs of age belonging to ASA-I undergoing elective general endotracheal anesthesia were selected for the study.

Results: There was marked decrease in HR after dexmedetomidine administration. In group D-0.6 and group D-1 HR, SBP, DBP and MAP markedly increased at 1 minute following laryngoscopy and
intubation in the control group where as in dexmedetomidine group there was a fall in HR, SBP, DBP and MAP at various intervals following intubation which was statistically significant. There was no statistical difference between the group D-0.6 and group D-1 with regard to haemodynamic parameters after laryngoscopy and endotracheal intubation. There was increased incidence of sedation in patients belonging to group D-1 when compared to group D-0.6 which was statistically significant. Incidence of bradycardia and hypotension was
higher in group D-1 when compared to group D-0.6 which were managed easily.

Conclusion: It is concluded that Dexmedetomidine obtunds the haemodynamic responses to laryngoscopy and endotracheal intubation
and 0.6 μg/kg body weight is the ideal dose for the same.